Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
FEBS Lett. 2011 Oct 20;585(20):3148-58. doi: 10.1016/j.febslet.2011.07.039. Epub 2011 Aug 5.
Despite great strides in our knowledge of the genetic and epigenetic changes underlying malignancy, we have limited information on the molecular basis of metastasis. Over 90% of cancer deaths are caused by spread of tumor cells from a primary site to distant organs and tissues, highlighting the pressing need to define the molecular effectors of cancer metastasis. Mounting evidence suggests that circulating tumor cells (CTCs) home to specific tissues by hijacking the normal leukocyte trafficking mechanisms. Cancer cells characteristically express CD44, and there is increasing evidence that hematopoietic cell E-/L-selectin ligand (HCELL), a sialofucosylated glycoform of CD44, serves as the major selectin ligand on cancer cells, allowing interaction of tumor cells with endothelium, leukocytes, and platelets. Here, we review the structural biology of CD44 and of HCELL, and present current data on the function of these molecules in mediating organ-specific homing/metastasis of CTCs.
尽管我们在恶性肿瘤的遗传和表观遗传变化方面取得了重大进展,但我们对转移的分子基础知之甚少。超过 90%的癌症死亡是由肿瘤细胞从原发部位扩散到远处的器官和组织引起的,这突出表明迫切需要定义癌症转移的分子效应物。越来越多的证据表明,循环肿瘤细胞 (CTC) 通过劫持正常白细胞迁移机制而归巢到特定组织。癌细胞特征性地表达 CD44,越来越多的证据表明,造血细胞 E-/L-选择素配体 (HCELL) 是 CD44 的唾液酸化糖基化形式,是癌细胞上主要的选择素配体,允许肿瘤细胞与内皮细胞、白细胞和血小板相互作用。在这里,我们回顾了 CD44 和 HCELL 的结构生物学,并介绍了这些分子在介导 CTC 器官特异性归巢/转移中的功能的最新数据。